What is Shattuck Labs Profitability Rank?
Shattuck Labs has the Profitability Rank of 1. It has had trouble to make a profit.
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way. It is based on these factors:
1.
Operating Margin %
2.
Piotroski F-Score
3. Trend of the
Operating Margin % (5-year average). The company with an uptrend profit margin has a higher rank.
4. Consistency of the profitability
5. Predictability Rank
Shattuck Labs's Operating Margin % for the quarter that ended in Mar. 2024 was -1,797.67%. As of today, Shattuck Labs's Piotroski F-Score is 2.
Competitive Comparison of Shattuck Labs's Profitability Rank
For the Biotechnology subindustry, Shattuck Labs's Profitability Rank, along with its competitors' market caps and Profitability Rank data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shattuck Labs's Profitability Rank Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Shattuck Labs's Profitability Rank distribution charts can be found below:
* The bar in red indicates where Shattuck Labs's Profitability Rank falls into.
Shattuck Labs Profitability Rank Calculation
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.
The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.
Shattuck Labs has the Profitability Rank of 1. It has had trouble to make a profit.
Profitability Rank is not directly related to the Financial Strength. But if a company is consistently profitable, its financial strength will be stronger.
Profitability Rank is based on these factors:
1. Operating Margin %
Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.
Shattuck Labs's Operating Margin % for the quarter that ended in Mar. 2024 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
2. Piotroski F-Score
Warning Sign:
Piotroski F-Score of 2 is low, which usually implies poor business operation.
The zones of discrimination were as such:
Good or high score = 8 or 9
Bad or low score = 0 or 1
Shattuck Labs has an F-score of 2. It is a bad or low score, which usually implies poor business operation.
3. Trend of the Operating Margin % (5-year average). The company with an uptrend profit margin has a higher rank.
Warning Sign:
Shattuck Labs Inc operating margin has been in a 5-year decline. The average rate of decline per year is -196.7%.
4. Consistency of the profitability
5. Predictability Rank
Shattuck Labs (Shattuck Labs) Business Description
Traded in Other Exchanges
N/A
Address
500 W. 5th Street, Suite 1200, Austin, TX, USA, 78701
Shattuck Labs Inc is a clinical-stage biotechnology company pioneering the development of dual-sided fusion proteins as an entirely new class of biologic medicine. Its product candidate, SL-172154, has been rationally designed to simultaneously inhibit the CD47/SIRPa checkpoint interaction to restore an anti-tumor immune response and to activate the CD40 costimulatory receptor to bolster an immune response. Its product candidate, SL-279252, which is being developed in collaboration with Takeda Pharmaceuticals, or Takeda, has been rationally designed to simultaneously inhibit the PD-1/PD-L1 interaction and activate the OX40 receptor.
Executives
| Andrew R Neill |
officer: See Remarks |
1018 W 11TH STREET, SUITE 100, AUSTIN TX 78703 |
| Stephen Stout |
officer: See Remarks |
C/O SHATTUCK LABS, INC., 500 W. 5TH STREET, SUITE 1200, AUSTIN TX 78701 |
| George Golumbeski |
director |
C/O CELGENE CORP., 86 MORRIS AVENUE, SUMMIT NJ 07901 |
| Abhinav A. Shukla |
officer: Chief Technical Officer |
500 W. 5TH STREET, SUITE 1200, AUSTIN TX 78701 |
| Carrie Brownstein |
director |
500 W. 5TH ST., SUITE 1200, AUSTIN TX 78701 |
| Erin Ator Thomson |
officer: General Counsel |
1018 W 11TH ST., SUITE 100, AUSTIN TX 78703 |
| Josiah Hornblower |
director, 10 percent owner, officer: Chairman |
3317 BOWMAN AVE, AUSTIN TX 78703 |
| Taylor Schreiber |
director, officer: Chief Executive Officer |
100 EUROPA DRIVE, CHAPEL HILL NC 27517 |
| Redmile Group, Llc |
director, 10 percent owner |
ONE LETTERMAN DRIVE, BUILDING D, SUITE D3-300, SAN FRANCISCO CA 94129 |
| Helen M Boudreau |
director |
200 TECHNOLOGY SQUARE, 4TH FLOOR, CAMBRIDGE MA 02139 |
| Neil W Gibson |
director |
C/O REGULUS THERAPEUTICS INC., 3545 JOHN HOPKINS COURT SUITE 210, SAN DIEGO CA 92121 |
| Tyler Brous |
director |
1018 W 11TH ST., SUITE 100, AUSTIN TX 78703 |
| Casi Deyoung |
officer: Chief Business Officer |
C/O MIRNA THERAPEUTICS, INC., 2150 WOODWARD ST., SUITE 100, AUSTIN TX 78744 |
| Arundathy N. Pandite |
officer: Chief Medical Officer |
1018 W 11TH ST., SUITE 100, AUSTIN TX 78703 |
| Victor Stone |
director |
1018 W 11TH ST., SUITE 100, AUSTIN TX 78703 |
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
STTK has been successfully added to your